Matthew Taylor
Stock Analyst at Jefferies
(3.25)
# 1,040
Out of 4,711 analysts
177
Total ratings
60%
Success rate
8.67%
Average return
Main Sectors:
Stocks Rated by Matthew Taylor
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABT Abbott Laboratories | Maintains: Hold | $120 → $125 | $114.23 | +9.43% | 12 | Oct 17, 2024 | |
| EW Edwards Lifesciences | Downgrades: Hold | $85 → $70 | $74.81 | -6.43% | 19 | Sep 18, 2024 | |
| PODD Insulet | Maintains: Neutral | $211 → $223 | $266.57 | -16.34% | 14 | Aug 9, 2024 | |
| INMD InMode | Downgrades: Hold | $21 → $19 | $17.08 | +11.24% | 6 | Jul 23, 2024 | |
| MDT Medtronic | Maintains: Sell | $75 → $76 | $81.03 | -6.21% | 17 | May 24, 2024 | |
| ALUR Allurion Technologies | Initiates: Buy | $5 | $0.35 | +1,336.78% | 1 | Feb 9, 2024 | |
| MASI Masimo | Downgrades: Hold | $107 → $121 | $169.52 | -28.62% | 9 | Jan 30, 2024 | |
| OBIO Orchestra BioMed Holdings | Initiates: Buy | $14 | $4.92 | +184.55% | 1 | Jan 19, 2024 | |
| GEHC GE HealthCare Technologies | Initiates: Hold | $80 | $78.91 | +1.38% | 1 | Nov 30, 2023 | |
| TNDM Tandem Diabetes Care | Maintains: Buy | $47 → $45 | $35.91 | +25.31% | 2 | Oct 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $0.5 | $0.46 | +8.74% | 1 | Jul 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $58 → $53 | $21.80 | +143.12% | 2 | Jul 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $22 → $24 | $14.16 | +69.49% | 2 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $320 → $345 | $364.60 | -5.38% | 14 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Hold | $115 → $130 | $107.12 | +21.36% | 8 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $230 | $242.54 | -5.17% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $13.25 | +50.94% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $85 | $68.63 | +23.85% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $82.63 | -9.23% | 7 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $245 | $237.27 | +3.26% | 7 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $88 | $55.45 | +58.70% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $62 | $29.50 | +110.17% | 8 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $210 | $178.16 | +17.87% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $9.35 | +28.34% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $125 | $80.04 | +56.17% | 12 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $88.95 | -43.79% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $210 | $524.43 | -59.96% | 12 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $31 | $3.79 | +717.94% | 5 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $96 | $47.59 | +101.72% | 3 | Feb 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $7 | $3.09 | +126.54% | 1 | Dec 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $266 | $227.68 | +16.83% | 4 | May 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $17 → $16 | $8.89 | +79.98% | 2 | Jul 19, 2017 |
Abbott Laboratories
Oct 17, 2024
Maintains: Hold
Price Target: $120 → $125
Current: $114.23
Upside: +9.43%
Edwards Lifesciences
Sep 18, 2024
Downgrades: Hold
Price Target: $85 → $70
Current: $74.81
Upside: -6.43%
Insulet
Aug 9, 2024
Maintains: Neutral
Price Target: $211 → $223
Current: $266.57
Upside: -16.34%
InMode
Jul 23, 2024
Downgrades: Hold
Price Target: $21 → $19
Current: $17.08
Upside: +11.24%
Medtronic
May 24, 2024
Maintains: Sell
Price Target: $75 → $76
Current: $81.03
Upside: -6.21%
Allurion Technologies
Feb 9, 2024
Initiates: Buy
Price Target: $5
Current: $0.35
Upside: +1,336.78%
Masimo
Jan 30, 2024
Downgrades: Hold
Price Target: $107 → $121
Current: $169.52
Upside: -28.62%
Orchestra BioMed Holdings
Jan 19, 2024
Initiates: Buy
Price Target: $14
Current: $4.92
Upside: +184.55%
GE HealthCare Technologies
Nov 30, 2023
Initiates: Hold
Price Target: $80
Current: $78.91
Upside: +1.38%
Tandem Diabetes Care
Oct 2, 2023
Maintains: Buy
Price Target: $47 → $45
Current: $35.91
Upside: +25.31%
Jul 19, 2023
Initiates: Underperform
Price Target: $0.5
Current: $0.46
Upside: +8.74%
Jul 12, 2023
Upgrades: Buy
Price Target: $58 → $53
Current: $21.80
Upside: +143.12%
May 24, 2023
Maintains: Hold
Price Target: $22 → $24
Current: $14.16
Upside: +69.49%
May 2, 2023
Maintains: Buy
Price Target: $320 → $345
Current: $364.60
Upside: -5.38%
Mar 31, 2023
Upgrades: Hold
Price Target: $115 → $130
Current: $107.12
Upside: +21.36%
Oct 12, 2022
Initiates: Buy
Price Target: $230
Current: $242.54
Upside: -5.17%
Oct 12, 2022
Initiates: Buy
Price Target: $20
Current: $13.25
Upside: +50.94%
Oct 12, 2022
Initiates: Hold
Price Target: $85
Current: $68.63
Upside: +23.85%
Oct 12, 2022
Initiates: Buy
Price Target: $75
Current: $82.63
Upside: -9.23%
Oct 12, 2022
Initiates: Hold
Price Target: $245
Current: $237.27
Upside: +3.26%
Oct 12, 2022
Initiates: Buy
Price Target: $88
Current: $55.45
Upside: +58.70%
Oct 12, 2022
Initiates: Hold
Price Target: $62
Current: $29.50
Upside: +110.17%
Oct 12, 2022
Initiates: Hold
Price Target: $210
Current: $178.16
Upside: +17.87%
Oct 12, 2022
Initiates: Buy
Price Target: $12
Current: $9.35
Upside: +28.34%
Oct 12, 2022
Initiates: Buy
Price Target: $125
Current: $80.04
Upside: +56.17%
Oct 12, 2022
Initiates: Buy
Price Target: $50
Current: $88.95
Upside: -43.79%
Oct 12, 2022
Initiates: Hold
Price Target: $210
Current: $524.43
Upside: -59.96%
Oct 12, 2022
Initiates: Underperform
Price Target: $31
Current: $3.79
Upside: +717.94%
Feb 24, 2022
Upgrades: Buy
Price Target: $96
Current: $47.59
Upside: +101.72%
Dec 17, 2021
Initiates: Neutral
Price Target: $7
Current: $3.09
Upside: +126.54%
May 13, 2019
Upgrades: Overweight
Price Target: $266
Current: $227.68
Upside: +16.83%
Jul 19, 2017
Maintains: Equal-Weight
Price Target: $17 → $16
Current: $8.89
Upside: +79.98%